# BLCO catalysts: Bausch & Lomb Corp PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/blco/catalysts

> Bausch & Lomb Corp (BLCO) has 2 upcoming catalysts. The next is the bl1107 low dose primary completion, February 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Bausch & Lomb Corp |
| Ticker | BLCO (NYSE) |
| SEC CIK | 1860742 |
| SIC | 3851 |
| SEC filings | https://sec-api.dev/companies/blco |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 11, 2016 | [Xiidra (lifitegrast) FDA approval](https://sec-api.dev/pdufa/lifitegrast) | BLCO |  | completed, approved | "NDA208073 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20160711, review_priority PRIORITY; sponsor_name BAUSCH AND LOMB INC; product XIIDRA (LIFITEGRAST)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208073%22)) |
| November 2, 2017 | [Vyzulta (latanoprostene bunod) FDA approval](https://sec-api.dev/pdufa/latanoprostene-bunod) | BLCO |  | completed, approved | "NDA207795 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20171102, review_priority STANDARD; sponsor_name BAUSCH AND LOMB; product VYZULTA (LATANOPROSTENE BUNOD)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207795%22)) |
| December 22, 2017 | [Lumify Preservative Free (brimonidine tartrate) FDA approval](https://sec-api.dev/pdufa/brimonidine) | BLCO |  | completed, approved | "NDA208144 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20171222, review_priority STANDARD; sponsor_name BAUSCH AND LOMB INC; product LUMIFY (BRIMONIDINE TARTRATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208144%22)) |
| February 22, 2019 | [Eysuvis (loteprednol etabonate) FDA approval](https://sec-api.dev/pdufa/loteprednol-etabonate) | BLCO |  | completed, approved | "NDA208219 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20190222, review_priority STANDARD; sponsor_name BAUSCH AND LOMB INC; product LOTEMAX SM (LOTEPREDNOL ETABONATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208219%22)) |
| October 22, 2021 | [Xipere (triamcinolone acetonide) FDA approval](https://sec-api.dev/pdufa/triamcinolone-acetonide) | BLCO |  | completed, approved | "NDA211950 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20211022, review_priority STANDARD; sponsor_name BAUSCH AND LOMB INC; product XIPERE (TRIAMCINOLONE ACETONIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211950%22)) |
| March 15, 2022 | [Atropine Sulfate (atropine sulfate) FDA approval](https://sec-api.dev/pdufa/atropine) | BLCO |  | completed, approved | "NDA213581 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20220315, review_priority STANDARD; sponsor_name BAUSCH AND LOMB INC; product ATROPINE SULFATE (ATROPINE SULFATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213581%22)) |
| May 18, 2023 | [Miebo (perfluorohexyloctane) FDA approval](https://sec-api.dev/pdufa/perfluorohexyloctane) | BLCO | To treat signs and symptoms of dry eye disease | completed, approved | "Miebo \| perfluorhexyloctane \| 5/18/2023 \| To treat signs and symptoms of dry eye diseaseDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)) |
| April 19, 2024 | [Lumify Preservative Free (brimonidine tartrate) FDA approval](https://sec-api.dev/pdufa/brimonidine) | BLCO |  | completed, approved | "NDA218424 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20240419, review_priority STANDARD; sponsor_name BAUSCH AND LOMB INC; product LUMIFY PRESERVATIVE FREE (BRIMONIDINE TARTRATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218424%22)) |
| June 29, 2025 | [Btos-ha primary completion](https://sec-api.dev/pdufa/btos-ha) | BLCO | Ocular Redness | completed | "NCT06803654 (A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-29 (ACTUAL); Lead Sponsor Bausch & Lomb Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06803654)) |
| May 18, 2026 | [Bl1107 low dose primary completion](https://sec-api.dev/pdufa/bl1107) | BLCO | Glaucoma | completed | "NCT07168902 (Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-18 (ACTUAL); Lead Sponsor Bausch & Lomb Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07168902)) |
| May 28, 2026 | [Xiidra (lifitegrast) primary completion](https://sec-api.dev/pdufa/lifitegrast) | BLCO | Dry Eye Disease | completed | "NCT07128628 (A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-28 (ACTUAL); Lead Sponsor Bausch & Lomb Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07128628)) |
| October 4, 2026 | [Topical ocular bl1332 low dose primary completion](https://sec-api.dev/pdufa/topical-ocular-bl1332) | BLCO | Pain, Postoperative | completed | "NCT07412496 (A Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative Ocular Pain Following Photorefractive Keratectomy): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-10-04 (ACTUAL); Lead Sponsor Bausch & Lomb Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07412496)) |
| Oct 2026 to Jan 2027 | [Topical ocular bl1332 low dose topline data readout](https://sec-api.dev/pdufa/topical-ocular-bl1332) | BLCO | Pain, Postoperative | scheduled | "NCT07412496 (A Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative Ocular Pain Following Photorefractive Keratectomy): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-10-04 (ACTUAL); Lead Sponsor Bausch & Lomb Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07412496)) |
| February 2027 | [Bl1107 low dose primary completion](https://sec-api.dev/pdufa/bl1107) | BLCO | Dry Eye Disease | scheduled | "NCT07778888 (BL1107 Response and Intensity Guided Dosing for Hyperemia Resolution Trial): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor Bausch & Lomb Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07778888)) |
| Feb to May 2027 | [Bl1107 low dose topline data readout](https://sec-api.dev/pdufa/bl1107) | BLCO | Dry Eye Disease | scheduled | "NCT07778888 (BL1107 Response and Intensity Guided Dosing for Hyperemia Resolution Trial): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor Bausch & Lomb Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07778888)) |

## Drugs

- [Atropine Sulfate (atropine sulfate)](https://sec-api.dev/pdufa/atropine): 
- [Bl1107 low dose](https://sec-api.dev/pdufa/bl1107): Dry Eye Disease, Glaucoma
- [Lumify Preservative Free (brimonidine tartrate)](https://sec-api.dev/pdufa/brimonidine): 
- [Btos-ha](https://sec-api.dev/pdufa/btos-ha): Ocular Redness
- [Vyzulta (latanoprostene bunod)](https://sec-api.dev/pdufa/latanoprostene-bunod): 
- [Xiidra (lifitegrast)](https://sec-api.dev/pdufa/lifitegrast): Dry Eye Disease
- [Miebo (perfluorohexyloctane)](https://sec-api.dev/pdufa/perfluorohexyloctane): To treat signs and symptoms of dry eye disease
- [Topical ocular bl1332 low dose](https://sec-api.dev/pdufa/topical-ocular-bl1332): Pain, Postoperative
- [Xipere (triamcinolone acetonide)](https://sec-api.dev/pdufa/triamcinolone-acetonide): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/blco/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "BLCO catalysts: Bausch & Lomb Corp PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/blco/catalysts

```bibtex
@misc{secapidev_companies_blco_catalysts_20261116,
  title        = {BLCO catalysts: Bausch & Lomb Corp PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/blco/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_blco_catalysts_20261116","title":"BLCO catalysts: Bausch & Lomb Corp PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/blco/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
